Actively Recruiting
A Phase 1 Study to Evaluate the Pharmacokinetic Interaction and Safety of ABBV-722 and Upadacitinib Following Multiple Oral Doses in Healthy Adult Subjects
Led by AbbVie · Updated on 2026-04-17
32
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a Phase 1 clinical trial to evaluate the safety and how the body processes two oral drugs, ABBV-722 and Upadacitinib, in healthy adult volunteers. The study aims to understand the interaction between these drugs when given multiple doses and to monitor any side effects that may occur. Participants will receive multiple oral doses of Upadacitinib, ABBV-722, or a combination of both during different periods of the study. The trial includes several groups and treatment periods, with dosing schedules extending up to 17 days in some periods. Healthy adults will be monitored closely throughout these treatment phases. During the study, participants will undergo various assessments including blood tests to measure drug levels in the body at different times, physical exams, vital sign checks, and ECGs. Researchers will track any adverse events for up to 91 days to evaluate safety. The study lasts several weeks, involving careful monitoring of how the drugs behave in the body and their safety profile.
CONDITIONS
Brief Title
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Laboratory values meet the criteria specified in the protocol.
- Generally good health based on medical history, physical exam, vital signs, lab tests, and ECG.
You will not qualify if you...
- History of any significant illness, infection, major fever, hospitalization, or surgery within 30 days before first dose.
- Chronic recurring infection or active viral infection.
- Use of alcohol, grapefruit, Seville oranges, starfruit, or quinine/tonic water within 72 hours before dosing.
- Use of tobacco or nicotine products within 90 days before first dose.
- Evidence of dysplasia or history of cancer except certain treated skin or cervical cancers.
- History or current active or latent tuberculosis.
- Prior exposure to ABBV-722 within 90 days before first dose of study drug.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 17 days across three treatment periods
Participants receive multiple oral doses of Upadacitinib, ABBV-722, or both in sequential periods to evaluate safety and how the body processes the drugs.
Multiple dosing visits during each period
Duration - Approximately up to 91 days
Participants are monitored for safety and adverse events after completing treatment.
Follow-up visits as scheduled up to 91 days post-treatment
Trial Site Locations
Total: 1 location
1
Acpru /Id# 279285
Grayslake, Illinois, United States, 60030
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here